Fukuda Hironori, Takagi Toshio, Kondo Tsunenori, Shimizu Satoru, Tanabe Kazunari
Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
Department of Urology, Tokyo Women's Medical University Medical Center East, Arakawa-ku, Tokyo, Japan.
Oncotarget. 2018 Feb 16;9(18):14296-14305. doi: 10.18632/oncotarget.24507. eCollection 2018 Mar 6.
Inflammation-based prognostic scores are useful for predicting survival in various cancers. Here, we aimed to determine the most useful inflammation-based prognostic score for predicting survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. We retrospectively analyzed the data of 152 patients who underwent cytoreductive nephrectomy for metastatic renal cell carcinoma between 1986 and 2015. In the multivariate stepwise analysis, the combination of age, Memorial Sloan-Kettering Cancer Center score, histology, sarcomatoid change, clinical nodal stage, brain metastasis, and liver metastasis was a significant predictor for survival (Harrell's concordance index [c-index]: 0.638). The c-index of the combination improved with the addition of an inflammation-based prognostic score: C-reactive protein (c-index: 0.672), Glasgow prognostic score (c-index: 0.674), neutrophil-to-lymphocyte ratio (c-index: 0.685), lymphocyte-to-monocyte ratio (c-index: 0.670), platelet-to-lymphocyte ratio (c-index: 0.666), systemic inflammation response index (c-index: 0.652), and systemic immune-inflammation index (c-index: 0.678). The neutrophil-to-lymphocyte ratio provided the greatest improvement in the c-index. Additional multivariate analysis showed that the neutrophil-to-lymphocyte ratio was an independent prognostic factor for survival ( 0.0001). The neutrophil-to-lymphocyte ratio was the most useful inflammation-based prognostic score for predicting survival in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
基于炎症的预后评分有助于预测各种癌症的生存率。在此,我们旨在确定用于预测接受减瘤性肾切除术的转移性肾细胞癌患者生存率的最有用的基于炎症的预后评分。我们回顾性分析了1986年至2015年间152例接受减瘤性肾切除术治疗转移性肾细胞癌患者的数据。在多因素逐步分析中,年龄、纪念斯隆凯特琳癌症中心评分、组织学、肉瘤样改变、临床淋巴结分期、脑转移和肝转移的组合是生存的显著预测因素(哈雷尔一致性指数[c指数]:0.638)。加入基于炎症的预后评分后,该组合的c指数有所提高:C反应蛋白(c指数:0.672)、格拉斯哥预后评分(c指数:0.674)、中性粒细胞与淋巴细胞比值(c指数:0.685)、淋巴细胞与单核细胞比值(c指数:0.670)、血小板与淋巴细胞比值(c指数:0.666)、全身炎症反应指数(c指数:0.652)和全身免疫炎症指数(c指数:0.678)。中性粒细胞与淋巴细胞比值使c指数提高最多。进一步的多因素分析表明,中性粒细胞与淋巴细胞比值是生存的独立预后因素(P<0.0001)。中性粒细胞与淋巴细胞比值是预测接受减瘤性肾切除术治疗的转移性肾细胞癌患者生存率最有用的基于炎症的预后评分。